Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Genelux Corporation (GNLX : NSDQ)

• Company Description    Genelux Corporation is a clinical-stage biopharmaceutical company. It focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company's most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus. Genelux Corporation is based in WESTLAKE VILLAGE, Calif. Number of Employees: 26

• Price / Volume Information    Yesterday's Closing Price: $2.89 Daily Weekly Monthly 20 Day Moving Average: 158,924 shares Shares Outstanding: 44.84 (millions) Market Capitalization: $129.59 (millions) Beta: 0.58 52 Week High: $8.54 52 Week Low: $2.29 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 0.70% -0.09% 12 Week 5.47% 2.89% Year To Date -33.72% -38.78%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2625 Townsgate Road Suite 230 - Westlake Village,CA 91361 USA ph: 805-267-9889 fax: - austin.murtagh@precisionaq.com http://www.genelux.com

• General Corporate Information    Officers Thomas Zindrick - Chief Executive Officer; President and Chairman Matthew Pulisic - Chief Financial Officer Mary Mirabelli - Director James L. Tyree - Director John Thomas - Director Peer Information Genelux Corporation (CORR.) Genelux Corporation (RSPI) Genelux Corporation (CGXP) Genelux Corporation (BGEN) Genelux Corporation (GTBP) Genelux Corporation (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 36870H103 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/06/26 Share - Related Items Shares Outstanding: 44.84 Most Recent Split Date: (:1) Beta: 0.58 Market Capitalization: $129.59 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.20 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.80 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/06/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 5.65 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 4.76% vs. Previous Quarter: 16.67% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/26 - - 03/31/26 - -174.55 12/31/25 - -153.29 ROA 06/30/26 - - 03/31/26 - -123.65 12/31/25 - -111.57 Current Ratio 06/30/26 - - 03/31/26 - 3.68 12/31/25 - 2.43 Quick Ratio 06/30/26 - - 03/31/26 - 3.68 12/31/25 - 2.43 Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - - 03/31/26 - -419,762.50 12/31/25 - -401,812.47 Book Value 06/30/26 - - 03/31/26 - 0.51 12/31/25 - 0.30 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00

Powered by Zacks Investment Research ©